Squarepoint
TRIB

Squarepoint’s Trinity Biotech TRIB Stock Holding History

Squarepoint’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,290
Closed -$137K – 3695
2021
Q1 		$137K Buy
+7,290
New +$175K ﹤0.01% 2825

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
NA
Navellier & Associates Reno, Nevada $960M AUM 79.37% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return
State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D Trenton, New Jersey $25.9B AUM 26.38% 1-Year Est. Return

Squarepoint's TRIB Position: Q2 2021 in Review

Squarepoint sold out of Trinity Biotech (TRIB) in Q2 2021, closing a stake of 7,290 shares — an estimated $137K sold.

Squarepoint first reported a position in TRIB in Q1 2021 and held it in 1 quarter. The position peaked at $137K in Q1 2021. 29 funds tracked by Wall St. Rank hold TRIB as of Q2 2021.

  • Squarepoint reported no remaining Trinity Biotech position as of Q2 2021 after selling out during the quarter.
  • Squarepoint sold 7,290 Trinity Biotech shares in Q2 2021, an estimated $137K.
  • Squarepoint first reported a position in Trinity Biotech in Q1 2021 and held it in 1 quarter.
  • Squarepoint's Trinity Biotech position peaked at $137K in Q1 2021.
  • 29 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2021.

Based on Squarepoint's 13F filing for Q2 2021, filed 16 Aug 2021.